Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07789106

A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists

A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists — Recruiting • Non-phase study • Diabetes / Metabolic • NCT07789106.

📅 19 Oct 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07789106
Start
2026-09-01
Completion
2027-12-01
ClinicaliQ Trial Snapshot
  • A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists — Recruiting • Non-phase study • Diabetes / Metabolic • NCT07789106.
  • Ubiquinol supplement versus placebo to reduce fatigue and preserve muscle strength in adults taking GLP-1 weight loss medications.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are: Does ubiquinol lower fatigue levels compared to a placebo (a look-alike capsule that contains no ubiquinol)? Does ubiquinol help maintain muscle strength during…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases
Diabetes / Metabolic · MHRA · 29 Jan 2026
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warni...
View brief →
Podcast
GLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
Diabetes / Metabolic · 00:15:32 · 03 Apr 2026
GLP-1 receptor agonists mimic gut-derived GLP-1: they increase glucose-dependent insulin release, suppress glucagon and slow gastric emptying. Semaglutide is a once-weekly GLP-1…
Listen →
Clinical Brief
New drug to stop ‘Ozempic butt’ muscle loss side effect of obesity jabs
Diabetes / Metabolic · BBC Health · 08 Jun 2026
Weight loss from GLP-1 receptor agonists results in approximately 33% muscle loss alongside fat loss, necessitating clinical attention to body composition changes…
View brief →
Clinical Brief
Why weight-loss jabs work better for some people than others
Diabetes / Metabolic · BBC Health · 10 Apr 2026
Genetic variations in appetite and digestion genes predict differential weight-loss responses to GLP-1 receptor agonists (Wegovy, Mounjaro), suggesting personalised medicine approaches may…
View brief →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Webinar
GLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
Diabetes / Metabolic · 0.5 · 05 Apr 2026
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline to review mechanism, evidence,…
Watch webinar →